TapImmune appoints Michael J. Loiacono as Chief Financial Officer

Loiacono will also act as Corporate Secretary

TapImmune, a clinical-stage immuno-oncology company specialising in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, is pleased to announce the appointment of Michael J. Loiacono as its Chief Financial Officer and Chief Accounting Officer.

Loiacono has served an advisory role to the company as finance consultant to TapImmune since March 2016.

Loiacono served as CFO of Global Axcess Corporation, a publicly traded company, from 2006–2013 where he was responsible for the overall strategy of the company including capital raises, mergers and acquisitions, corporate finance, treasury, accounting and investor relations.

Upon the acquisition of Global Axcess by FCTI, he was responsible for the company's strategic development including new products and services, entrance into new markets and maximising gross and net revenues.

Prior to Global Axcess/FCTI, Loiacono held various positions of increasing responsibility in finance management through several private and publicly traded organizations. He has a degree in Business Management from Rutgers University, Business School (NJ, USA).

Dr Glynn Wilson, Chairman and CEO of TapImmune, stated: ‘We welcome Michael to a key position in the TapImmune management team. As an adviser to the company, Michael has clearly demonstrated his financial skills and ability to professionally lead our finance and accounting functions consistent with our projected uplist to the Nasdaq National Markets.’

‘It's truly an exciting opportunity to join an industry leader such as TapImmune and be a part of the management team,’ said Mr Loiacono. ‘The company has become a leader in the area of immuno-oncology as a result of innovative science, passionate employees and talented researchers.I look forward to working with this fantastic team as we continue to forge ahead in this very important industry and bring increased value to our shareholders.’

You may also like